Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Sulfosuccinimidyl oleate sodium (SSO sodium salt) is a long chain fatty acid acting as an irreversible inhibitor of the fatty acid translocase CD36, blocking uptake of oleate, linoleate, or stearate by about 65% when added at 200 µM to adipocytes. SSO is also a potent and irreversible inhibitor of mitochondrial respiratory chain.
ln Vitro |
Cell viability was unaffected by SuLfosuccinimidyl oleate (20 μM and 50 μM, 24 hours) alone. Changes in exposure to 100 ng/mL LPS+5 ng/mL IFNγ led to a significant decrease in the viability of BV2 cells. In BV2 cells stimulated by LPS+IFNγ, co-treatment with 50 μM SuLfosuccinimidyl oleate for 24 hours dramatically decreased the production of NOS2 and COX-2. By co-treating with SuLfosuccinimidyl oleate (50 μM, 24 hours), one may prevent the considerable elevation of the phosphorylated form of p38 that was caused by LPS/IFNγ, according to Western blot analysis [1].
|
---|---|
ln Vivo |
In model BALB/cABom with pMCAO model, SuLfosuccinimidyl oleate (50 mg/kg; distilled once via a single sidewall tube catheter) significantly reduced neck infarct size compared with vehicle-treated controls. Additionally, 50 mg/kg of sulfosuccinimide oil ester is suitable to see good results after stroke [1].
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: BV2 Cell Tested Concentrations: 50 μM Incubation Duration: 24 hrs (hours) Experimental Results: NOS2, COX-2 and P-p38/T-p38 levels were Dramatically increased. |
Animal Protocol |
Animal/Disease Models: 4-month-old male BALB/cABom mouse pMCAo model [1]
Doses: 50 mg/kg Route of Administration: Administration once via single po (oral gavage). Experimental Results: Reduce post-ischemic brain damage. The infarct area is diminished. |
References |
[1]. Dhungana H, et al. Sulfosuccinimidyl oleate sodium is neuroprotective and alleviates stroke-induced neuroinflammation. J Neuroinflammation. 2017 Dec 4;14(1):237.
[2]. Drahota Z, et al. Succinimidyl oleate, established inhibitor of CD36/FAT translocase inhibits complex III of mitochondrial respiratory chain. Biochem Biophys Res Commun. 2010 Jan 15;391(3):1348-51. |
Molecular Formula |
C22H36NNAO7S
|
---|---|
Molecular Weight |
481.578516960144
|
Exact Mass |
481.21101794
|
CAS # |
1212012-37-7
|
Related CAS # |
Sulfosuccinimidyl oleate;135661-44-8
|
Appearance |
Solid
|
SMILES |
CCCCCCCC/C=C\CCCCCCCC(=O)ON1C(=O)CC(C1=O)S(=O)(=O)[O-].[Na+]
|
InChi Key |
FZVVLJSNKVOPRF-KVVVOXFISA-M
|
InChi Code |
InChI=1S/C22H37NO7S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(25)30-23-20(24)18-19(22(23)26)31(27,28)29;/h9-10,19H,2-8,11-18H2,1H3,(H,27,28,29);/q;+1/p-1/b10-9-;
|
Chemical Name |
sodium;1-[(Z)-octadec-9-enoyl]oxy-2,5-dioxopyrrolidine-3-sulfonate
|
Synonyms |
Sulfosuccinimidyl Oleate sodium; Sulfo-N-succinimidyl oleate sodium
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 47~62.5 mg/mL (97.4~129.8 mM)
Ethanol: ~3 mg/mL (~6.2 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 3.33 mg/mL (6.91 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Solubility in Formulation 4: 3.33 mg/mL (6.91 mM) in 0.5% Methylcellulose/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0765 mL | 10.3825 mL | 20.7650 mL | |
5 mM | 0.4153 mL | 2.0765 mL | 4.1530 mL | |
10 mM | 0.2076 mL | 1.0382 mL | 2.0765 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.